EUVIMEDEUVIMED entdecken
Crossref

Dihydroartemisinin inhibited stem cell‐like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling

Yujun Wang, Zhirong Yang, Wanglong Zhu, Yuzhuo Chen, Xingqiang He, Jiaofeng Li, Zhengyu Han, Yuhan Yang, Wei Liu, Kun Zhang iD

Drug Development Research · 2023

DOI: 10.1002/ddr.22067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2023. Verfasst von Yujun Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Chengdu Medical College, Chengdu, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Colorectal Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a common tumor with high morbidity and mortality. The use of oxaliplatin (L‐OHP) as a first‐line treatment for CRC is limited due to chemoresistance. Growing evidence have revealed that the existence of cancer stem‐like cells (CSLCs) is one of the important reasons for drug resistance and recurrence of cancers. Dihydroartemisinin (DHA), a derivative of artemisinin, has showed anticancer effects on a variety of malignancies, in addition to its antimalarial effects. However, the effect and mechanism of DHA on CSLCs and chemosensitivity in CRC cells remains unclear. In this study, we found that DHA inhibited cell viability in HCT116 and SW620 cells. Moreover, DHA decreased cell clonogenicity, and improved L‐OHP sensitivity. Furthermore, DHA treatment attenuated tumor sphere formation, and the expressions of stem cell surface marker (CD133 and CD44) and stemness‐associated transcription factor (Nanog, c‐Myc, and OCT4). Mechanistically, the present findings showed that DHA inhibited of AKT/mTOR signaling pathway. The activation of AKT/mTOR signaling reversed DHA‐decreased cell viability, clonogenicity, L‐OHP resistance, tumor sphere, and expressions of stemness‐associated protein in CRC. The inhibitory effect of DHA on tumorigenicity of CRC cells has also been demonstrated in BALB/c nude mice. In conclusion, this study revealed that DHA inhibited CSLCs properties in CRC via AKT/mTOR signaling, suggesting that DHA may be used as a potential therapeutic agent for CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktColorectal NeoplasmsAnimalsMiceOxaliplatinMice, NudeSignal TransductionTOR Serine-Threonine KinasesNeoplastic Stem CellsCell Line, TumorCell ProliferationArtemisinins

Stichwörter der Autor:innen

AKT/mTOR signalingcancer stem-like cellscolorectal cancerdihydroartemisininresistance

Substanzen

OxaliplatinProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesartenimolArtemisinins

Autor:innen und Institutionen

  • School of Pharmacy, Chengdu Medical College, Chengdu, China.
  • The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu, China.
  • Pathology Department, Deyang People's Hospital, Deyang, China.
  • School of Biological Sciences and Technology, Chengdu Medical College, Chengdu, China.
  • College of Laboratory Medicine, Chengdu Medical College, Chengdu, China.

ORCID-Profile: Kun Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, Y., Yang, Z., Zhu, W., Chen, Y., He, X., Li, J., Han, Z., Yang, Y., Liu, W., & Zhang, K. (2023). Dihydroartemisinin inhibited stem cell‐like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling. Drug Development Research. https://doi.org/10.1002/ddr.22067

Vancouver

Wang Y, Yang Z, Zhu W, Chen Y, He X, Li J, et al. Dihydroartemisinin inhibited stem cell‐like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling. Drug Development Research. 2023. doi:10.1002/ddr.22067

BibTeX
@article{Wang2023,
  author = {Wang, Yujun and Yang, Zhirong and Zhu, Wanglong and Chen, Yuzhuo and He, Xingqiang and Li, Jiaofeng and Han, Zhengyu and Yang, Yuhan and Liu, Wei and Zhang, Kun},
  title = {Dihydroartemisinin inhibited stem cell‐like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling},
  journal = {Drug Development Research},
  year = {2023},
  doi = {10.1002/ddr.22067}
}
Kostenlos starten →